1354 completed, 544 terminated, 396 recruiting, 271 unknown. 3029 Phase 1, 1031 Phase 2.
Follow Leukemia: new trials by email Literature Review of Leukemia trials Research Report on Leukemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients with AML Donor-derived CD34+ HSC with CRISPR/Cas9-mediated CD33 deletion, Gemtuzumab Ozogamicin - Relapsed/Refractory Acute Myeloid Leukemia (AML) | Phase 1 | Not yet recruiting | German Cancer Research Center | 12 | 2028-01-01 | 2025-03-14 |
| A Phase 1 Open-Label, Dose-Ranging Safety and Pharmacokinetics Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML) Cytarabine, Oral Cladribine - Acute Myeloid Leukemia (AML) | Phase 1 / Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 58 | 2027-12-01 | 2026-08-25 |
| CAR-T Immunotherapy Targeting CD19- ALL 4SCAR-CD22/CD123/CD38/CD10/CD20/TSLPR - B-cell Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2027-07-01 | 2026-11-02 |
| Universal 4SCAR7U Targeting CD7-positive Malignancies Universal CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Universal CAR-T Cells Targeting AML CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells - Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2027-06-30 | 2026-11-02 |
| Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Autologous BAFFR-targeting CAR T Cells, Biospecimen Collection, Bone Marrow Aspiration - Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma | Phase 1 | Recruiting | City of Hope Medical Center | 16 | 2027-04-17 | 2026-11-13 |
| Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI. CAR-T anti-CD19 COL01 - Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia, Lymphoid Malignancies | Phase 1 | Not yet recruiting | GUSTAVO SALGUERO | 12 | 2027-04-01 | 2026-10-20 |
| Maintenance Treatment With Imetelstat in Patients With High-Risk Myeloid Neoplasms After Allo-SCT imetelstat - High-risk Myeloid Malignancy, Allogenic Stem Cell Transplantation | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 27 | 2027-02-01 | 2026-11-02 |
| Axatilimab Combined With Decitabine/Venetoclax for the Treatment of TP53-mutated AML Decitabine, Venetoclax, Axatilimab - Acute Myeloid Leukemia, TP53 Gene Mutation | Phase 1 | Not yet recruiting | Northside Hospital, Inc. | 32 | 2027-01-31 | 2026-10-16 |
| Roginolisib Plus Obinutuzumab + Venetoclax in R/R CLL Roginolisib, Obinutuzumab, Venetoclax - Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 40 | 2027-01-13 | 2026-09-29 |
| Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome Monzosertib, Posaconazole, Isavuconazole - Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome | Phase 1 | Not yet recruiting | M.D. Anderson Cancer Center | 42 | 2027-01-01 | 2026-08-21 |
| GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors VTRU200 - Acute Myeloid Leukemia, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Not yet recruiting | Vitruviae | 108 | 2027-01-01 | 2026-08-06 |
| huCART19-IL18-CD428z Cells for the Treatment of Patients With HIV With CD19+ Cancers huCART19-IL18-CD428z cells - Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia | Phase 1 | Not yet recruiting | University of Pennsylvania | 6 | 2027-01-01 | 2026-11-02 |
| Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies CD7-specific CAR gene-engineered T cells - T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 30 | 2026-12-31 | 2026-11-02 |
| Multi-CAR T Cell Therapy for Acute Myeloid Leukemia Muc1/CLL1/CD33/CD38/CD56/CD123-specific gene-engineered T cells - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 10 | 2026-12-31 | 2026-11-02 |
| BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 | Not yet recruiting | City of Hope Medical Center | 19 | 2026-12-14 | 2026-05-13 |
| A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia sonrotoclax, Azacitidine, Inotuzumab ozogamicin - Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | BeOne Medicines | 30 | 2026-12-01 | 2026-10-26 |
| CD19 CAR-T Cell Therapy in Adults With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: A Phase I/II Study MB-CART19.1 - Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Hospital Universitario Dr. Jose E. Gonzalez | 30 | 2026-12-01 | 2026-10-22 |
| A Study of LP-118 In Combination With Ponatinib, Dexamethasone And Blinatumomab For Adults With Newly-Diagnosed, BCR::ABL1-Positive Acute Lymphoblastic Leukemia (ALL) LP-118 - Philadelphia Positive Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Wake Forest University Health Sciences | 26 | 2026-12-01 | 2026-10-29 |
| FH-WT1-E50 TCR T Cells With Azacitidine for the Treatment of Minimal Residual Disease Positive Acute Myeloid Leukemia Autologous HLA-A*02:01-restricted CD4+/CD8+ Anti-WT1 TCR/CD8ab-expressing T-cells, Azacitidine, Biospecimen Collection - Acute Myeloid Leukemia | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 9 | 2026-12-01 | 2026-10-29 |
Showing 20 of 3029. Sign in to see all of them.
Leukemia, Myeloid, Acute (1480) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (838) · Leukemia, Lymphocytic, Chronic, B-Cell (794) · Myelodysplastic Syndromes (573) · Lymphoma, Non-Hodgkin (485) · Lymphoma (430) · Lymphoma, Mantle-Cell (365) · Lymphoma, Follicular (356) · Lymphoma, Large B-Cell, Diffuse (347) · Recurrence (318) · Burkitt Lymphoma (308) · Lymphoma, B-Cell, Marginal Zone (303) · Hodgkin Disease (248) · Multiple Myeloma (238)
Hemic and Lymphatic Diseases (3028) · Neoplasms by Histologic Type (3016) · Hematologic Diseases (3007) · Neoplasms (2887) · Immune System Diseases (1732) · Immunoproliferative Disorders (1722) · Lymphoproliferative Disorders (1704) · Lymphatic Diseases (1695) · Leukemia, Myeloid (1690) · Leukemia, Lymphoid (1492) · Pathological Conditions, Signs and Symptoms (1462) · Pathologic Processes (1460) · Disease Attributes (1428) · Chronic Disease (1201)
Cytarabine (300) · Cyclophosphamide (266) · fludarabine (218) · venetoclax (207) · Azacitidine (205) · fludarabine phosphate (172) · Rituximab (134) · Decitabine (108) · Filgrastim (100) · Etoposide (84) · Methotrexate (77) · Dexamethasone (74) · Lenalidomide (69) · Peripheral Blood Stem Cell Transplantation (68) · Granulocyte Colony-Stimulating Factor (66)
National Cancer Institute (NCI) (214) · M.D. Anderson Cancer Center (189) · Fred Hutchinson Cancer Center (60) · City of Hope Medical Center (55) · Memorial Sloan Kettering Cancer Center (45) · Novartis Pharmaceuticals (45) · Dana-Farber Cancer Institute (37) · Washington University School of Medicine (32) · AbbVie (30) · Baylor College of Medicine (30) · Masonic Cancer Center, University of Minnesota (27) · Celgene (26) · St. Jude Children's Research Hospital (26) · Bristol-Myers Squibb (25) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (25)
United States (2118) · China (352) · France (208) · Germany (182) · Canada (178) · Spain (171) · Australia (159) · Italy (146) · United Kingdom (143) · Japan (83) · Netherlands (81) · South Korea (78) · Belgium (58) · Poland (57) · Israel (53)
Jorge Cortes, MD (13) · Farhad Ravandi-Kashani, MD (9) · Jae Park, MD (9)
PMID 34515338, PMID 41671463, PMID 34398557, PMID 42013378, PMID 28054442, PMID 32499241, PMID 41429239, PMID 24615776, PMID 24615777, PMID 33883258, PMID 34687939, PMID 34889384, PMID 35622074, PMID 35829925, PMID 37486616, PMID 38507688, PMID 39368878, PMID 40195173, PMID 16775234, PMID 19238148, PMID 19949018, PMID 20028764, PMID 20882050, PMID 21816833, PMID 22002018, PMID 23660685, PMID 23886836, PMID 24055823, PMID 24615778, PMID 24782509, PMID 25317870, PMID 25381051, PMID 26182309, PMID 26813675, PMID 26943915, PMID 27400247, PMID 27482888, PMID 28280089, PMID 28877686, PMID 29296805, PMID 31023700, PMID 31355467, PMID 31527168, PMID 31723767, PMID 32508818, PMID 33067379, PMID 33197925, PMID 33208914, PMID 33394722, PMID 33741715
P30CA033572 (38), 2023 (31), P30CA015704 (25), 2018 (22), U01CA076576 (22), P30CA016672 (21), 2015 (20), P30CA006973 (19), U01CA070095 (18), 2016 (17), 2014 (15), 2025 (14), P30CA016058 (14), 2017 (12), 2019 (12)